DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS™) therapies, announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application for CRC01, CD19 CAR-T cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL). This study is expected to be initiated in the first half of 2021.
"We are excited to receive Korea's first IND clearance for a CAR-T therapy," said Gunsoo Kim, CEO of Curocell. "OVIS™ is a unique CAR-T platform that combines CAR-T with immune checkpoint receptor inhibition. This unique technology can be a breakthrough for patients who are difficult to treat with conventional CD19 CAR-T."
About CRC01
CRC01, recognized CD19 and is based on OVIS™, a first in class CAR-T platform co-developed with KAIST. OVIS™ downregulates PD1 and TIGIT in the same viral vector, designed to express a CAR protein, allowing cost-effective and simple manufacturing. Curocell holds the global development and commercial rights for CRC01 and OVIS™.
About Curocell
Curocell, based in Daejeon, South Korea, is clinical-stage biotech innovating CAR-T therapies. Curocell is developing OVIS™ CAR-T therapies with the goal of reducing non-responding patients who receive CAR-T therapy. Curocell established a GMP facility in Samsung Medical Center, one of the largest cancer centers in Asia with 655 beds. For more information, visit curocellbtx.com/en.
View original content:http://www.prnewswire.com/news-releases/curocell-announces-korean-fda-clearance-of-the-ind-for-crc01-a-first-in-kind-immune-checkpoint-receptors-downregulated-cd19-car-t-therapy-301232233.html
